logo
  

Biogen Idec Inc. (BIIB) Is Up Sharply After Q2 Profit Topped Expectations

Biogen Idec Inc. (BIIB) reported second quarter non-GAAP EPS of $3.49 Wednesday morning, up from $2.30 last year. Analysts expected EPS of $2.83. The company now expects to report full year non-GAAP EPS of $12.90 to $13.10, up from prior guidance of $11.35 to $11.45. The consensus estimate is for EPS of $11.53.

Biogen Idec gapped open sharply higher this morning and is now up 37.09 at $340.76 on above average volume. The stock has broken out of a 2-month range and has set a 4-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT